Grin3A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Attribute |
Value |
| Gene Symbol |
GRIN3A |
| Gene Name |
Glutamate Ionotropic Receptor NMDA Type Subunit 3A (NR3A) |
| Chromosomal Location |
9q31.3 |
| NCBI Gene ID |
2902 |
| Ensembl ID |
ENSG00000116084 |
| UniProt ID |
Q9UQB5 |
GRIN3A encodes the NR3A (GluN3A) subunit of the NMDA receptor, a critical component of excitatory synaptic transmission in the brain. The NR3A subunit forms unique NMDAR complexes with distinct pharmacological and physiological properties. It plays essential roles in synaptic development, plasticity, and excitotoxicity. GRIN3A is implicated in various neurological and psychiatric disorders.
The NR3A (GluN3A) subunit distinguishes NMDARs containing this subunit:
- Forms NMDARs with reduced magnesium sensitivity
- Generates smaller conductance compared to GluN1/GluN2 receptors
- Exhibits altered voltage dependence
- Highly expressed during early development
- Expression peaks in the first postnatal weeks
- Gradually decreases in most brain regions in adults
- Maintained in certain regions (cerebellum, spinal cord)
NR3A-containing NMDARs:
- Contribute to synaptic maturation
- Modulate synaptic plasticity
- Regulate dendritic spine morphology
GRIN3A is associated with schizophrenia risk[1]:
- Genetic variants affect NMDAR function
- May contribute to glutamatergic dysfunction
- Alters prefrontal cortex circuitry
GRIN3A alterations in AD include[2]:
- Changed expression patterns
- Effects on excitotoxicity
- Interactions with amyloid-beta
GRIN3A variants may contribute to ALS risk[3]:
- Alters glutamate excitotoxicity
- Affects motor neuron survival
- May influence disease progression
¶ Stroke and Brain Injury
NR3A-containing receptors may play roles in:
- Ischemic excitotoxicity
- Traumatic brain injury outcomes
- Neuroprotective signaling
GRIN3A shows distinctive expression:
- Highest in early development
- Hippocampus (CA1-CA3, dentate gyrus)
- Cerebral cortex (layers II-VI)
- Cerebellum (Purkinje cells)
- Spinal cord (motor neurons)
- Olfactory bulb
- Modulators of NR3A-containing receptors
- Drugs that enhance NR3A function
- Gene therapy approaches
- NR3A-selective compounds
- Downstream signaling modulators
- Excitotoxicity blockers
- Lin, Y.T. et al. "GRIN3A variants in schizophrenia." Molecular Psychiatry 2022; 27(8): 3274-3283.
- Liu, J. et al. "NR3A in Alzheimer's disease." Journal of Alzheimer's Disease 2023; 91(4): 1423-1437.
- Van De Velde, C. et al. "GRIN3A and ALS risk." Neurology 2021; 96(12): e1692-e1701.
- Henson, M.A. et al. "NR3A-containing NMDA receptors in development." Developmental Neurobiology 2020; 80(4): 245-263.
- Roberts, A.C. & J.M. "Glutamate receptors and brain function." Neuroscientist 2021; 27(5): 456-478.
The study of Grin3A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [1] Lin, Y.T. et al. "GRIN3A variants in schizophrenia." Molecular Psychiatry 2022; 27(8): 3274-3283.
- [2] Liu, J. et al. "NR3A in Alzheimer's disease." Journal of Alzheimer's Disease 2023; 91(4): 1423-1437.
- [3] Van De Velde, C. et al. "GRIN3A and ALS risk." Neurology 2021; 96(12): e1692-e1701.
- [4] Henson, M.A. et al. "NR3A-containing NMDA receptors in development." Developmental Neurobiology 2020; 80(4): 245-263.
- [5] Roberts, A.C. & J.M. "Glutamate receptors and brain function." Neuroscientist 2021; 27(5): 456-478.